ReviewCNS drugs2005
Zonisamide: a review of its use in the management of partial seizures in epilepsy.
Review in CNS drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 37 citations in OpenAlex.
- Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction.Metabolomics : Official journal of the Metabolomic Society · 2018Trial
- Efficacy of zonisamide in migraineurs with nonresponse to topiramate.BioMed research international · 2014Trial
- Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration.Pharmaceutical research · 2020Article
- Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.CNS drugs · 2017Review
- Zonisamide in the management of epilepsy in the elderly.Clinical interventions in aging · 2015Review
- Zonisamide: a review of its use as adjunctive therapy in the management of partial seizures in pediatric patients aged ≥6 years.Paediatric drugs · 2014Review
- Review
- Thalamic T-type Ca²+ channels mediate frontal lobe dysfunctions caused by a hypoxia-like damage in the prefrontal cortex.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011Article
- Zonisamide: in Parkinson's disease.CNS drugs · 2009Article
- Use of second-generation antiepileptic drugs in the pediatric population.Paediatric drugs · 2008Review
- Suicidality and antiepileptic drugs: is there a link?Drug safety · 2007Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zonisamide (Zonegran, Excegran) is a new-generation, broad-spectrum antiepileptic drug (AED) currently approved as adjunctive therapy for the treatment of medically refractory partial seizures in adults in the US and as adjunctive therapy or monotherapy in the control of partial and generalised seizures in adults and children in Japan and Korea. Either as adjunctive therapy or monotherapy, zonisamide effectively reduces the frequency of partial seizures, with or without secondary generalisation to tonic-clonic seizures, in adults and children with epilepsy. The drug is generally well tolerated and, additionally, has a favourable pharmacokinetic profile permitting once- or twice-daily administration. Direct head-to-head comparisons with other AEDs would be beneficial in fully defining the place of zonisamide in therapy. In the meantime, adjunctive therapy or monotherapy with zonisamide is a convenient, useful option for the management of partial seizures, including those refractory to other AEDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.